Dietary LPC-Bound n-3 LCPUFA Protects against Neonatal Brain Injury in Mice but Does Not Enhance Stem Cell Therapy
Nutrients · 2024
DOI: 10.3390/nu16142252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Eva C Hermans und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht Universit…. Hauptthemen laut MEDLINE: Mice, Inbred C57BL, Fatty Acids, Omega-3, Lysophosphatidylcholines, Animals, Newborn. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelmina Children's Hospital, Wilhelmina’s Children’s Hospital Research Fund, Aker Biomarine.
Abstract (Originalsprache)
Neonatal hypoxic-ischemic (HI) brain injury is a prominent cause of neurological morbidity, urging the development of novel therapies. Interventions with n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) and mesenchymal stem cells (MSCs) provide neuroprotection and neuroregeneration in neonatal HI animal models. While lysophosphatidylcholine (LPC)-bound n-3 LCPUFAs enhance brain incorporation, their effect on HI brain injury remains unstudied. This study investigates the efficacy of oral LPC-n-3 LCPUFAs from Lysoveta following neonatal HI in mice and explores potential additive effects in combination with MSC therapy. HI was induced in 9-day-old C57BL/6 mice and Lysoveta was orally supplemented for 7 subsequent days, with or without intranasal MSCs at 3 days post-HI. At 21–28 days post-HI, functional outcome was determined using cylinder rearing, novel object recognition, and open field tasks, followed by the assessment of gray (MAP2) and white (MBP) matter injury. Oral Lysoveta diminished gray and white matter injury but did not ameliorate functional deficits following HI. Lysoveta did not further enhance the therapeutic potential of MSC therapy. In vitro, Lysoveta protected SH-SY5Y neurons against oxidative stress. In conclusion, short-term oral administration of Lysoveta LPC-n-3 LCPUFAs provides neuroprotection against neonatal HI by mitigating oxidative stress injury but does not augment the efficacy of MSC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht University, 3508 AB Utrecht, The Netherlands.
- Aker BioMarine Human Ingredients AS, Oksenøyveien 10, 1327 Lysaker, Norway.
ORCID-Profile: Carlon C E van Gerven, Caroline G M de Theije
Förderung
- Wilhelmina Children's Hospital
- Wilhelmina’s Children’s Hospital Research Fund
- Aker Biomarine
Zitieren
APA
Hermans, E. C., van Gerven, C. C. E., Johnsen, L., Tungen, J. E., Nijboer, C. H., & de Theije, C. G. M. (2024). Dietary LPC-Bound n-3 LCPUFA Protects against Neonatal Brain Injury in Mice but Does Not Enhance Stem Cell Therapy. Nutrients. https://doi.org/10.3390/nu16142252
Vancouver
Hermans EC, van Gerven CCE, Johnsen L, Tungen JE, Nijboer CH, de Theije CGM. Dietary LPC-Bound n-3 LCPUFA Protects against Neonatal Brain Injury in Mice but Does Not Enhance Stem Cell Therapy. Nutrients. 2024. doi:10.3390/nu16142252
BibTeX
@article{Hermans2024,
author = {Hermans, Eva C and van Gerven, Carlon C E and Johnsen, Line and Tungen, Jørn E and Nijboer, Cora H and de Theije, Caroline G M},
title = {Dietary LPC-Bound n-3 LCPUFA Protects against Neonatal Brain Injury in Mice but Does Not Enhance Stem Cell Therapy},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16142252}
}
EUVIMED